Yeah obviously we've interpreted differently and I can see how you derived your outcome. Either way it bodes well, and demonstrates the huge upside (assuming it goes to plan) of AGN. As reported it doesn't even touch the ramifications on the upside to the share price of the following:
We have ascribed no value for secondary indications of hypoxic
ischaemic encephalopathy, traumatic brain injury, or global brain
ischemia. We will look to eventually incorporate these as clinical
development progresses. We further note these indications have large
market opportunities.
What a stock to hold!!!!
Ann: SRC Approves Commencement Of Fourth And Final Cohort Dosing, page-10
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
83.0¢ |
Change
-0.015(1.78%) |
Mkt cap ! $102.6M | |||
| Open | High | Low | Value | Volume |
| 84.5¢ | 85.5¢ | 82.0¢ | $69.84K | 82.78K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2733 | 82.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 84.5¢ | 3700 | 1 |
View Market Depth
| Last trade - 15.58pm 05/07/2024 (20 minute delay) ? |
| AGN (ASX) Chart |